149 related articles for article (PubMed ID: 31527074)
1. Genetic characterization of B-cell prolymphocytic leukemia: a prognostic model involving MYC and TP53.
Chapiro E; Pramil E; Diop M; Roos-Weil D; Dillard C; Gabillaud C; Maloum K; Settegrana C; Baseggio L; Lesesve JF; Yon M; Jondreville L; Lesty C; Davi F; Le Garff-Tavernier M; Droin N; Dessen P; Algrin C; Leblond V; Gabarre J; Bouzy S; Eclache V; Gaillard B; Callet-Bauchu E; Muller M; Lefebvre C; Nadal N; Ittel A; Struski S; Collonge-Rame MA; Quilichini B; Fert-Ferrer S; Auger N; Radford-Weiss I; Wagner L; Scheinost S; Zenz T; Susin SA; Bernard OA; Nguyen-Khac F; ;
Blood; 2019 Nov; 134(21):1821-1831. PubMed ID: 31527074
[TBL] [Abstract][Full Text] [Related]
2. Aberrations of MYC are a common event in B-cell prolymphocytic leukemia.
Flatley E; Chen AI; Zhao X; Jaffe ES; Dunlap JB; Pittaluga S; Abdullah S; Olson SB; Spurgeon SE; Fan G
Am J Clin Pathol; 2014 Sep; 142(3):347-54. PubMed ID: 25125625
[TBL] [Abstract][Full Text] [Related]
3. B cell prolymphocytic leukaemia (B-PLL) with complex karyotype and concurrent abnormalities of the p53 and c-MYC gene.
Lens D; Coignet LJ; Brito-Babapulle V; Lima CS; Matutes E; Dyer MJ; Catovsky D
Leukemia; 1999 Jun; 13(6):873-6. PubMed ID: 10360375
[TBL] [Abstract][Full Text] [Related]
4. MYC rearranged B-cell neoplasms: Impact of genetics on classification.
Haberl S; Haferlach T; Stengel A; Jeromin S; Kern W; Haferlach C
Cancer Genet; 2016 Oct; 209(10):431-439. PubMed ID: 27810071
[TBL] [Abstract][Full Text] [Related]
5. Mutational and cytogenetic analyses of 188 CLL patients with trisomy 12: A retrospective study from the French Innovative Leukemia Organization (FILO) working group.
Roos-Weil D; Nguyen-Khac F; Chevret S; Touzeau C; Roux C; Lejeune J; Cosson A; Mathis S; Feugier P; Leprêtre S; Béné MC; Baron M; Raynaud S; Struski S; Eclache V; Sutton L; Lesty C; Merle-Béral H; Cymbalista F; Ysebaert L; Davi F; Leblond V;
Genes Chromosomes Cancer; 2018 Nov; 57(11):533-540. PubMed ID: 30203893
[TBL] [Abstract][Full Text] [Related]
6. Chronic lymphocytic leukemia and prolymphocytic leukemia with MYC translocations: a subgroup with an aggressive disease course.
Put N; Van Roosbroeck K; Konings P; Meeus P; Brusselmans C; Rack K; Gervais C; Nguyen-Khac F; Chapiro E; Radford-Weiss I; Struski S; Dastugue N; Gachard N; Lefebvre C; Barin C; Eclache V; Fert-Ferrer S; Laibe S; Mozziconacci MJ; Quilichini B; Poirel HA; Wlodarska I; Hagemeijer A; Moreau Y; Vandenberghe P; Michaux L;
Ann Hematol; 2012 Jun; 91(6):863-73. PubMed ID: 22205151
[TBL] [Abstract][Full Text] [Related]
7. Effective upfront treatment with low-dose ibrutinib for a patient with B cell prolymphocytic leukemia.
Oka S; Ono K; Nohgawa M
Invest New Drugs; 2020 Oct; 38(5):1598-1600. PubMed ID: 31965420
[TBL] [Abstract][Full Text] [Related]
8. B and T cell prolymphocytic leukaemia.
Cross M; Dearden C
Best Pract Res Clin Haematol; 2019 Sep; 32(3):217-228. PubMed ID: 31585622
[TBL] [Abstract][Full Text] [Related]
9. Ibrutinib therapy is effective in B-cell prolymphocytic leukemia exhibiting MYC aberrations.
Damlaj M; Al Balwi M; Al Mugairi AM
Leuk Lymphoma; 2018 Mar; 59(3):739-742. PubMed ID: 28695755
[No Abstract] [Full Text] [Related]
10. T-cell prolymphocytic leukemia frequently shows cutaneous involvement and is associated with gains of MYC, loss of ATM, and TCL1A rearrangement.
Hsi AC; Robirds DH; Luo J; Kreisel FH; Frater JL; Nguyen TT
Am J Surg Pathol; 2014 Nov; 38(11):1468-83. PubMed ID: 25310835
[TBL] [Abstract][Full Text] [Related]
11. Prolymphocytic Leukemia: New Insights in Diagnosis and in Treatment.
Collignon A; Wanquet A; Maitre E; Cornet E; Troussard X; Aurran-Schleinitz T
Curr Oncol Rep; 2017 Apr; 19(4):29. PubMed ID: 28324286
[TBL] [Abstract][Full Text] [Related]
12. T-cell prolymphocytic leukemia: an aggressive T cell malignancy with frequent cutaneous tropism.
Magro CM; Morrison CD; Heerema N; Porcu P; Sroa N; Deng AC
J Am Acad Dermatol; 2006 Sep; 55(3):467-77. PubMed ID: 16908353
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of cytogenetic abnormalities in T-cell prolymphocytic leukemia.
Hu Z; Medeiros LJ; Fang L; Sun Y; Tang Z; Tang G; Sun T; Quesada AE; Hu S; Wang SA; Pei L; Lu X
Am J Hematol; 2017 May; 92(5):441-447. PubMed ID: 28194886
[TBL] [Abstract][Full Text] [Related]
14. Combining MYC, BCL2 and TP53 gene and protein expression alterations improves risk stratification in diffuse large B-cell lymphoma.
Fiskvik I; Beiske K; Delabie J; Yri O; Spetalen S; Karjalainen-Lindsberg ML; Leppä S; Liestøl K; Smeland EB; Holte H
Leuk Lymphoma; 2015 Jun; 56(6):1742-9. PubMed ID: 25284491
[TBL] [Abstract][Full Text] [Related]
15. MYC Expression Is Associated With p53 Expression and TP53 Aberration and Predicts Poor Overall Survival in Acute Lymphoblastic Leukemia/Lymphoma.
Gao L; Harbaugh B; Parr K; Patel P; Golem S; Zhang D; Woodroof J; Cui W
Am J Clin Pathol; 2022 Jan; 157(1):119-129. PubMed ID: 34528662
[TBL] [Abstract][Full Text] [Related]
16. Expression of c-myc oncoprotein in chronic T cell leukemias.
Maljaie SH; Brito-Babapulle V; Matutes E; Hiorns LR; De Schouwer PJ; Catovsky D
Leukemia; 1995 Oct; 9(10):1694-9. PubMed ID: 7564512
[TBL] [Abstract][Full Text] [Related]
17. Genetic characterization of T-PLL reveals two major biologic subgroups and JAK3 mutations as prognostic marker.
Stengel A; Kern W; Zenger M; Perglerová K; Schnittger S; Haferlach T; Haferlach C
Genes Chromosomes Cancer; 2016 Jan; 55(1):82-94. PubMed ID: 26493028
[TBL] [Abstract][Full Text] [Related]
18. The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype.
Dicker F; Herholz H; Schnittger S; Nakao A; Patten N; Wu L; Kern W; Haferlach T; Haferlach C
Leukemia; 2009 Jan; 23(1):117-24. PubMed ID: 18843282
[TBL] [Abstract][Full Text] [Related]
19. An extensive molecular cytogenetic characterization in high-risk chronic lymphocytic leukemia identifies karyotype aberrations and TP53 disruption as predictors of outcome and chemorefractoriness.
Rigolin GM; Formigaro L; Cavallari M; Quaglia FM; Lista E; Urso A; Guardalben E; Martinelli S; Saccenti E; Bassi C; Lupini L; Bardi MA; Volta E; Tammiso E; Melandri A; Negrini M; Cavazzini F; Cuneo A
Oncotarget; 2017 Apr; 8(17):28008-28020. PubMed ID: 28427204
[TBL] [Abstract][Full Text] [Related]
20. A complex pattern of recurrent chromosomal losses and gains in T-cell prolymphocytic leukemia.
Soulier J; Pierron G; Vecchione D; Garand R; Brizard F; Sigaux F; Stern MH; Aurias A
Genes Chromosomes Cancer; 2001 Jul; 31(3):248-54. PubMed ID: 11391795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
